Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis
NCT00439647 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1199
Last updated 2017-04-21
Summary
This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.
Conditions
- Male Osteoporosis
Interventions
- DRUG
-
Zoledronic acid 5 mg iv
Zoledronic acid 5 mg iv given once a year.
- DRUG
-
Placebo intravenous (i.v.) once a year
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Argentina
-
Novartis Pharmaceuticals · Novartis Belgium
-
Novartis Pharmaceuticals · Novartis Brazil
-
Novartis Pharmaceuticals · Novartis Czech Republic
-
Novartis Pharmaceuticals · Novartis Denmark
-
Novartis Pharmaceuticals · Novartis Finland
-
Novartis Pharmaceuticals · Novartis Germany
-
Novartis Pharmaceuticals · Novartis Hungary
-
Novartis Pharmaceuticals · Novartis Norway
-
Novartis Pharmaceuticals · Novartis Portugal
-
Novartis Pharmaceuticals · Novartis Romania
-
Novartis Pharmaceuticals · Novartis Spain
-
Novartis Pharmaceuticals · Novartis Slovakia
-
Novartis Pharmaceuticals · Novartis Sweden
-
Novartis Pharmaceuticals · Novartis
-
Novartis Pharmaceuticals · Novartis United Kingdom
-
Novartis Pharmaceuticals · Novartis Australia
-
Novartis Pharmaceuticals · Novartis Italy
-
Novartis Pharmaceuticals · Novartis Austria
-
Novartis Pharmaceuticals · Novartis Iceland
-
Novartis Pharmaceuticals · Novartis Poland
-
Novartis Pharmaceuticals · Novartis Russia
-
Novartis Pharmaceuticals · Novartis (South Africa)
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 50 Years
- Max Age
- 85 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-12-31
- Primary Completion
- 2010-10-31
- Completion
- 2010-10-31
Countries
- Argentina
- Australia
- Austria
- Belgium
- Brazil
- Czechia
- Denmark
- Finland
- Germany
- Hungary
- Iceland
- Italy
- Norway
- Poland
- Portugal
- Romania
- Russia
- Slovakia
- South Africa
- Spain
- Sweden
- Switzerland
- United Kingdom
Study Locations
More Related Trials
-
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
NCT00439244 ·Status: COMPLETED ·Phase: PHASE3
-
Intra-venous Zoledronic Acid Once Yearly
NCT00984893 ·Status: COMPLETED
-
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
NCT00718861 ·Status: COMPLETED ·Phase: PHASE3
-
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
NCT00404820 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
NCT00980174 ·Status: COMPLETED ·Phase: PHASE3
-
Zoledronic Acid for Osteoporosis in the Elderly
NCT00558012 ·Status: COMPLETED ·Phase: NA
-
A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate
NCT00100555 ·Status: COMPLETED ·Phase: PHASE3
-
Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)
NCT00145327 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate the Efficacy and Safety After Administration of Daewoong Zoledronic Acid for the Purpose of Treatment or Prevention of Osteoporosis
NCT05614778 ·Status: COMPLETED
-
Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
NCT00680953 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid
NCT04719650 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
NCT00103740 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis
NCT00004406 ·Status: COMPLETED ·Phase: NA
-
Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty
NCT01267279 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Zoledronic Acid in Osteoporosis
NCT03183557 ·Status: UNKNOWN ·Phase: PHASE2
-
Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid
NCT00097812 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis
NCT00100620 ·Status: COMPLETED ·Phase: PHASE3
-
Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid
NCT00745485 ·Status: COMPLETED ·Phase: PHASE4
-
TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density
NCT05391776 ·Status: UNKNOWN ·Phase: PHASE1
-
Bisphosphonate Treatment of Osteogenesis Imperfecta
NCT00063479 ·Status: COMPLETED ·Phase: PHASE2
-
Osteoporosis in Primary Hyperparathyroidism
NCT04085419 ·Status: UNKNOWN ·Phase: PHASE4
-
Denosumab vs Zoledronic Acid and Osteoporotic Compression Fracture
NCT05106517 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women
NCT00361595 ·Status: COMPLETED ·Phase: NA
-
To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women
NCT00145275 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)
NCT01120600 ·Status: COMPLETED ·Phase: PHASE3